Drug intelligence / Profile preview

DPV-009

Development stage: Unknown
Lead developer: UbiVac
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

DPV-009 is a therapeutic cancer vaccine candidate developed by Diaccurate. It is designed as a multi-epitope vaccine targeting specific tumor-associated antigens to stimulate a robust T-cell mediated immune response against cancer cells. The vaccine is part of Diaccurate's oncology pipeline, which focuses on high-unmet-need indications. DPV-009 is typically administered via subcutaneous injection and is often evaluated in combination with other immunotherapies, such as checkpoint inhibitors, to enhance anti-tumor efficacy by overcoming immune evasion mechanisms within the tumor microenvironment.

Beyond the preview

Go deeper on DPV-009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DPV-009.

Explore the full profile